Alector, Inc. (ALEC)
Alector, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in South San Francisco, CA, US. The stock last traded at $2.09, up 23.67% on the session, giving a market capitalisation of $232.0M. On trailing twelve-month figures it carries a trailing P/E of -1.90, a net margin of -850.1%. Its beta of 0.58 implies it has historically moved less than the broad market.
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
Alector, Inc. is most often compared with the following Healthcare names: